A study investigating a new drug called Garadacimab for people with IPF

Upcoming study
Expected to open January 2022
This study is currently recruiting
Expected to close November 2023
This study is closed
This study closed in November 2023
We will update this page with study results when available.
Information on study results are included below
This study closed in November 2023
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

This study is a randomised control trial which is investigating the effects of a new drug called Garadacimab.

The study aims to see how the body responds to the drug and the effect it has for people with IPF.

 – 

What is involved?

You will be assigned at random to one of two groups. You will either receive the study drug, Garadacimab, or a lookalike drug which does not contain any active medication (placebo). Both the study drug and placebo are given as an injection and through a 'drip' (intravenous infusion) where a fluid is delivered into the body through a vein. You will have a number of different medical assessments, such as blood tests, and monitoring for up to 22 weeks.

Neither you or the researchers will know who has been given the active drug or the placebo until after the study has ended. This is to ensure truly understand the effect of the new drug.

Summary of involvement

Participation for up to 22 weeks

Single intravenous infusion and injection of either the study drug or a placebo

Monitoring of how the body responds to the drug through medical assessments

Can I take part?

You may be able to take part if you have a confirmed diagnosis of IPF, are 40 years and older, and have no clinically significant heart, blood pressure or bleeding disorders.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the clinical trial team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Male or Female

Diagnosis of IPF

You will not be able to join the study of any of the following applies:

History of significant heart problems

History of uncontrolled high blood pressure

Problems with current bleeding or clotting disorders

What difference could taking part make?

People affected by idiopathic pulmonary fibrosis (IPF) currently have limited treatment options to slow the progression of disease. New research studies such as this, help us to gain valuable knowledge about potentially better treatment options.

Taking part in this study would enable researchers to identify if the study drug is well tolerated and safe for people diagnosed with IPF. The study will help to gain understanding of the safety of the drug and how the body responds, for future investigations in further research studies.

Where does the study take place?

Study locations

Oxford

Birmingham

Londonderry

Manchester

How to take part

Further information

The summary on this page provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

clinicaltrials@cslbehring.com

This study is supported by

CSL Behring
Study ID number:
NCT05130970

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org